Skip to main content
. Author manuscript; available in PMC: 2021 Jul 21.
Published in final edited form as: Clin Cancer Res. 2020 Jul 2;26(18):4777–4784. doi: 10.1158/1078-0432.CCR-20-0700

Figure 4. Pharmacodynamic effects in tumor tissue.

Figure 4

Biopsies were done at the dose level of 180 mg thrice a week. Phosphorylation of cofilin normalized to GAPDH at baseline and at 15 - 28 days of intermittent dosing was assayed using an immuno-chemiluminescence assays and results are presented as percentage of pre-dose levels (A) A reduction of more than 50% of p-cofilin levels were seen in 3/8 patients. (B) Phosphorylation of MLC2 was measured by IHC in pre- and post-treatment tumor specimens of patients treated with AT13148 showing reduction in phosphorylation in only 1/5 samples.